Dergiler / Medicine Science / 2016 / Cilt: 5 - Sayı: 1

The Effect of Hydroxychloroquine Treatment on Blood Sugar Level, Serum Lipid Profile and the Retina in Systemic Lupus Erythematosus Patients

Sayfa
57–71
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

HCQ has beneficial effects in protection against thrombosis, hyperglycemia and the absence of retina toxicity in the short term of the use

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:The aim of this study was to evaluate the effect of hydroxychloroquine (HCQ) on blood sugar level, lipid profile and retina in newly diagnosed systemic lupus erythromatosus (SLE) patients.
📊
Temel Bulgular & Veri:They were with a mean (SD, range) age 30 (7.07, 25, 35) years old.
💡
Sonuç & Katkı:HCQ has beneficial effects in protection against thrombosis, hyperglycemia and the absence of retina toxicity in the short term of the use
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

The aim of this study was to evaluate the effect of hydroxychloroquine (HCQ) on blood sugar level, lipid profile and retina in newly diagnosed systemic lupus erythromatosus (SLE) patients. Fifty newly diagnosed SLE patients were collected from Immunology and Rheumatology outpatient clinics in Beni Suef University hospital. All patient's questionnaire included name, age, sex, smoking status, the date of the diagnosis, drugs taken during the follow up period and present history of other diseases. Only HCQ was prescribed to the patients within one year follow-up. They were with a mean (SD, range) age 30 (7.07, 25, 35) years old. Their total lipid profile which included total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL) and fasting blood sugar (FBG) and postprandial blood glucose levels (PPBG) were analyzed in MASTER LAB in Beni suef before and after 6 months from the using of HCQ as well as our patients were converted to Ophthalmology Department in Beni Suef University hospital before and at the end of six months of HCQ therapy to undergo to complete eye examinations. The mean (SD) of TC, TG, LDL, FBG and PPBG were significantly decreased after HCQ than before using it while HDL was increased at p<0.05. There was no observed effect on retina. HCQ has beneficial effects in protection against thrombosis, hyperglycemia and the absence of retina toxicity in the short term of the use

🔖

Bu Makaleye Atıf Yap

SALEM, H. F., HAMİD, M. N. A. E., AHMED, A. S., SARHANL, R. M. (2016). The Effect of Hydroxychloroquine Treatment on Blood Sugar Level, Serum Lipid Profile and the Retina in Systemic Lupus Erythematosus Patients. Medicine Science, Cilt: 5 - Sayı: 1, 57–71. https://ajindex.com/articles/277680

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Ballestar E, Esteller M, Richardson BC. The epigenetic face of systemic lupus erythematosus. Immunol. 2006; 176(12):7143 —7. Bertsias G, Gordon C, Boumpas D. Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future—the EULAR recommendations for the management of SLE and the use of end—points in clinical trials. Lupus. 2008;17(5):437—42. Dörner T, Therapy: hydroxychloroquine in SLE: old drug, new perspectives. Nature Reviews Rheumatology. 2010;6(1):10-1.
  2. Solomon DH, Garg R, Lu B, Todd DJ, Mercer E, Norton T, Massarotti E. The effect of hydroxychloroquine on insulin sensitivity and lipid parameters in non-diabetic patients with rheumatoid arthritis: randomized blinded cross-over trial. Arthritis Care Res. 2014;66(8):l246—51. Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol. 2012;130(4):461—9. Cairoli E, Rebella M, Danese N, Garra V, Borba EF. Hydroxychloroquine reduces low—density lipoprotein cholesterol levels in systemic lupus erythematosus: longitudinal evaluation of the lipid—lowering effect. Lupus. 2012;21(1 1):1 178—82. Kim JS, Oh JS, Chang EA, Bae SY, Nam DH, Lee CH, Yang JH, Lee CK, Lee WJ, Kim HC, Klein TA, Lim CS, Kim YK. Alteration of platelet counts and lipid profiles after treatment of acute Plasmodium vivaX Acta Tropica. 2008;106(1):39—43. Nikpour M, Gladman DD, lbanez D, Harvey PJ, Urowitz MB. Research article Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: longitudinal cohort study. Arthritis Res Ther. 2010;12(3):R125. Kang L, Mikuls TR, O’Dell JR. Reminder of important clinical lesson: Hydroxychloroquine: diabetic drug in disguise? BMJ Case Rep. 2009;20092bcr0820080654. Wasko, MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, Ward MM., Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298(2):187—93. Bili A, Sartorius JA, Kirchner HL, Morris SJ, Ledwich LJ, Antohe JL, Dancea S, Newman ED, Wasko MC. Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. Clin Rheumatol. 2011;17(3):115-20.
  3. Mercer E, Rekedal L, Garg R, Lu B, Massarotti EM, Solomon DH. Hydroxychloroquine improves insulin sensitivity in obese non—diabetic individuals. Arthritis Res Ther. 2012;14(3):R135. Penn S.K, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, Manzi S, Wasko MC. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and